Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

283.80DKK
1 Oct 2014
Price Change (% chg)

kr.1.80 (+0.64%)
Prev Close
kr.282.00
Open
kr.281.50
Day's High
kr.286.20
Day's Low
kr.281.20
Volume
2,753,825
Avg. Vol
2,165,542
52-wk High
kr.286.20
52-wk Low
kr.179.60

NOVOb.CO

Chart for NOVOb.CO

About

Novo Nordisk A/S is a healthcare company. The Company is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. It is engaged in diabetes care. It has a range of diabetes product portfolio, including a portfolio of modern insulins and the first human once-daily GLP-1 analog. In addition,... (more)

Overall

Beta: 1.05
Market Cap (Mil.): kr.595,743.12
Shares Outstanding (Mil.): 2,112.56
Dividend: 4.50
Yield (%): 1.60

Financials

  NOVOb.CO Industry Sector
P/E (TTM): 28.90 33.37 34.07
EPS (TTM): 9.76 -- --
ROI: 65.79 18.15 17.40
ROE: 71.98 18.85 18.25
Search Stocks

Novo Nordisk's next big idea: a once-weekly insulin shot

COPENHAGEN - Denmark's Novo Nordisk, the world's largest insulin maker, is betting on a new way to stay ahead in the $40 billion-plus diabetes market by trying to develop the world's first once-weekly insulin injection.

01 Oct 2014

NORDIC STOCKS - Factors to watch on Sept 19

HELSINKI, Sept 19 - The following stocks may be affected by newspaper reports and other factors on Friday:

19 Sep 2014

Novo's Ryzodeg effective in type 2 diabetes treatment: study

COPENHAGEN - Novo Nordisk's type 2 diabetes treatment Ryzodeg has proved effective in providing good blood sugar control with fewer injections than a so-called basal-bolus treatment, according to new data from a late-stage study.

18 Sep 2014

Novo's Ryzodeg effective in type 2 diabetes treatment -study

COPENHAGEN, Sept 18 - Novo Nordisk's type 2 diabetes treatment Ryzodeg has proved effective in providing good blood sugar control with fewer injections than a so-called basal-bolus treatment, according to new data from a late-stage study.

18 Sep 2014

NORDIC STOCKS-Factors to watch on Sept 17

COPENHAGEN, Sept 17 - The following stocks may be affected by newspaper reports and other factors on Wednesday:

17 Sep 2014

Study shows Novo's new diabetes drug effective and safe for children

COPENHAGEN - Novo Nordisk's new long-acting insulin Tresiba has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage trial presented on Tuesday.

16 Sep 2014

Study shows Novo's new diabetes drug effective and safe for children

COPENHAGEN, Sept 16 - Novo Nordisk's new long-acting insulin Tresiba has been shown to be effective and safe for long-term use in children and young adults with type 1 diabetes, according to new data from a late-stage trial presented on Tuesday.

16 Sep 2014

U.S. FDA panel: Novo Nordisk's liraglutide safe, effective for obesity

WASHINGTON - Novo Nordisk's drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

12 Sep 2014

Executive view: Novo Nordisk to increase its focus on obesity

COPENHAGEN - Novo Nordisk's liraglutide drug is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration (FDA) said on Thursday.

12 Sep 2014

U.S. FDA panel: Novo Nordisk's liraglutide safe, effective for obesity

WASHINGTON - Novo Nordisk's drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday.

11 Sep 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$ 20.00
Provider: MacroRisk Analytics/EconomicInvestor
$ 25.00
Provider: ValuEngine, Inc.
$ 25.00
Provider: Wright Reports
$ 75.00
Provider: Reuters Investment Profile
$ 20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks